Key result
Atrial natriuretic peptide significantly inhibited AngII-induced increases in cardiomyocyte size (from 176% to 107%, p<0.05) and superoxide generation, suggesting an antioxidant antihypertrophic action.
Why the study?
Does atrial natriuretic peptide reduce hypertrophy and superoxide generation in neonatal rat cardiomyocytes exposed to hypertrophic stimuli?
Does atrial natriuretic peptide reduce hypertrophy and superoxide generation in neonatal rat cardiomyocytes exposed to hypertrophic stimuli?
p-value: p=<0.05
ANP exerts antihypertrophic effects in neonatal rat cardiomyocytes partly by reducing superoxide levels, suggesting an antioxidant mechanism.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; extends preclinical evidence for ANP antioxidant effects in hypertrophy.
Laskowski et al. (2006) studied Cardiac hypertrophy (in vitro model). Atrial natriuretic peptide (ANP) vs. Angiotensin II (AngII) or Endothelin-1 (ET1) alone was evaluated on Cardiomyocyte size, superoxide generation, and expression of hypertrophy markers (p=<0.05). Atrial natriuretic peptide significantly inhibited AngII-induced increases in cardiomyocyte size (from 176% to 107%, p<0.05) and superoxide generation, suggesting an antioxidant antihypertrophic action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: